Study on mesenchymal stem cells in promoting engraftment and preventing graft-versus-host disease for umbilical cord blood stem cell transplantation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060761

Enrollment

Unknown

Registered

2022-06-10

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Umbilical cord blood stem cell transplantation in the treatment of rare diseases in children

Interventions

Group 1:Infusion of mesenchymal stem cells

Eligibility

Sex/Gender

All

Age

No minimum to 17 Years

Inclusion criteria

Inclusion criteria: 1. Children who received umbilical cord blood stem cell transplantation in the Department of Hematology of our hospital; 2. The legal guardian of the patient has the desire to receive mesenchymal stem cell treatment, fully understands the relevant contents and risks of the treatment, signs the informed consent, and is willing to abide by the treatment plan and follow-up plan.

Exclusion criteria

Exclusion criteria: 1. Unstable vital signs; 2. Previous infusion of mesenchymal stem cells had serious complications (such as infusion related anaphylactic shock, infusion related severe organ damage, etc.).

Design outcomes

Primary

Measure	Time frame
Chimerism rate;Neutrophil engraftment time;platelet engraftment time;Incidence of graft versus host disease;	—

Secondary

Measure	Time frame
overall survival rate;disease free survival rate;	—

Countries

China

Contacts

Public ContactZhai Xiaowen

Children's Hospital of Fudan University

xwzhai@fudan.edu.cn+86 18017590808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026